Mangoceuticals, Inc. (MGRX) 股票分析

公司概述

Mangoceuticals, Inc. operates within the healthcare sector, specifically focusing on the health information services industry by developing, marketing, and selling men's wellness products and services through a telemedicine platform in the United States. The company's core offerings include erectile dysfunction products under the Mango brand, hair loss products under the Grow brand, and hormone balance solutions, all delivered via a direct-to-consumer telehealth model. This specialized business model positions the firm as a niche player targeting specific wellness needs rather than providing broad pharmaceutical coverage. Currently, the company maintains a market capitalization of $5.77 million, generates annual revenue of $456,021, and employs a workforce of three individuals. These valuation and operational metrics indicate that Mangoceuticals functions as a micro-cap entity with minimal operational scale, suggesting that its revenue generation relies heavily on high-margin direct sales rather than established distribution networks or significant human capital infrastructure.

财务健康

The company reported a trailing twelve-month revenue of $456,021, yet this revenue figure masks a substantial net income loss of $-21,818,994, while the EBITDA stands at $-15,869,579. The stark discrepancy between the modest revenue of $456,021 and the massive net loss reveals an extremely aggressive cost structure where operating expenses vastly exceed income, resulting in a profit margin of 0.0%. Despite these significant operational losses, the company reports a free cash flow of $1.88 million, which suggests a degree of financial flexibility potentially derived from cash reserves rather than operational profitability. The balance sheet shows cash holdings of $1.49 million against total debt of $307,823, creating a net cash position that temporarily buffers the company against its leverage, although the debt-to-equity ratio of 2.02 indicates a highly leveraged capital structure relative to equity. Liquidity is supported by a current ratio of 1.74, indicating that the company possesses sufficient current assets to cover its short-term obligations, though the margin of safety is constrained by the small asset base. Return on Equity is reported at -141.7% and Return on Assets at -69.9%, metrics that demonstrate management has been unable to generate positive returns on the shareholders' capital or the assets employed in the business.

估值评估

Valuation multiples for Mangoceuticals, Inc. are unavailable in traditional forms, with both the P/E Ratio (TTM) and Forward P/E listed as N/A due to the absence of positive net income. The Price to Book ratio is 0.30, indicating that the market values the company at a significant discount to its book value, which often occurs with distressed or pre-revenue-stage biotech firms. Alternative valuation metrics provide further insight, with a Price to Sales ratio of 12.65 and an EV/EBITDA of -0.29, suggesting the market is pricing the stock based on asset backing or potential future growth rather than current earnings power. Regarding price volatility, the stock has traded between a 52-week low of $0.16 and a 52-week high of $2.88, with the current market cap of $5.77 million implying a share price that sits within this historical trading range. The stock exhibits a Beta of 2.55, which signifies that the share price is highly sensitive to market movements, typically fluctuating with 2.55 times the magnitude of the broader market index.

Growth & Income

The company's financial trajectory shows a Revenue Growth (YoY) of -10.3%, while Earnings Growth (YoY) is listed as N/A due to the negative earnings base. The decline in revenue of 10.3% suggests a contraction in the telemedicine platform's user base or product sales, and since the company is unprofitable, the concept of earnings growing faster than revenue is not applicable in the traditional sense. As Mangoceuticals does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all cash flows, including its free cash flow of $1.88 million, for reinvestment into product development or to service its debt obligations. The overall growth and income profile is characterized by declining revenue and significant operational losses, relying entirely on existing cash reserves to fund operations without the support of shareholder distributions or positive earnings generation.